LAB
What one share of Standard BioTools holds
Pharmaceutical Preparations
At Standard BioTools, Inc. ("Standard BioTools" or the "Company"), we are committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team.
Standard BioTools’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.22 |
|---|---|
| Profit | $0.22 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.21 |
| Cash and investments | $0.69 |
| Book value | $1.38 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $3.60 | −$2.62 | $0.17 | −$1.52 | — | $1.82 |
| 2017 | $3.09 | −$1.84 | $0.05 | −$0.78 | — | $0.80 |
| 2018 | $2.85 | −$1.49 | $0.01 | −$0.64 | — | $1.46 |
| 2019 | $1.76 | −$0.97 | $0.04 | −$0.57 | — | $2.20 |
| 2020 | $1.92 | −$0.74 | $0.18 | −$0.39 | — | $1.87 |
| 2021 | $1.72 | −$0.78 | $0.17 | −$0.76 | — | $1.23 |
| 2022 | $1.25 | −$2.43 | $0.05 | −$1.19 | — | −$1.02 |
| 2023 | $1.34 | −$0.94 | $0.04 | −$0.58 | — | −$1.85 |
| 2024 | $0.26 | −$0.52 | $0.02 | −$0.43 | — | $1.25 |
| 2025 | $0.22 | −$0.20 | $0.02 | −$0.22 | — | $1.10 |